Plasmablastic lymphoma

Plasmablast, Wright stain

Plasmablastic Lymphoma (PBL) is a rare and aggressive form of non-Hodgkin lymphoma that is most commonly associated with HIV infection but can also occur in individuals without HIV. It was first described in the late 1990s and is characterized by its rapid progression and poor prognosis. Plasmablastic lymphoma is distinguished from other lymphomas by its unique histological and immunophenotypic features, which resemble those of plasma cells rather than B-cells, the usual origin of non-Hodgkin lymphomas.

Etiology and Pathogenesis

The exact cause of plasmablastic lymphoma is not fully understood, but it is closely associated with immunosuppression, particularly in individuals with HIV/AIDS. It has also been linked to other conditions that cause immune suppression, such as organ transplantation and the use of immunosuppressive drugs. The role of Epstein-Barr virus (EBV) has been noted in many cases of PBL, suggesting a possible oncogenic trigger in the context of immunosuppression.

Clinical Presentation

Patients with plasmablastic lymphoma typically present with rapidly enlarging masses, often in extranodal sites such as the oral cavity, gastrointestinal tract, and skin. Systemic symptoms such as fever, night sweats, and weight loss (collectively known as B symptoms) may also be present. Due to its aggressive nature, PBL can quickly lead to significant morbidity and mortality if not diagnosed and treated promptly.

Diagnosis

The diagnosis of plasmablastic lymphoma is based on histological and immunophenotypic analysis of tumor tissue. Histologically, PBL is characterized by large neoplastic cells with immunoblastic/plasmablastic morphology. Immunophenotyping typically shows loss of B-cell markers with retention of plasma cell markers, distinguishing it from other types of lymphoma. Additional tests, including molecular and genetic studies, may be performed to further characterize the tumor and guide treatment decisions.

Treatment

Treatment of plasmablastic lymphoma is challenging due to its aggressive nature and the poor condition of many patients at diagnosis. The mainstay of treatment is intensive chemotherapy, often followed by consolidation with autologous stem cell transplantation in eligible patients. Antiretroviral therapy is also crucial for patients with HIV-associated PBL to control HIV infection and improve immune function. Despite aggressive treatment, the prognosis for plasmablastic lymphoma remains poor, with high rates of relapse and mortality.

Prognosis

The prognosis of plasmablastic lymphoma is generally poor, with low overall survival rates reported in most studies. Factors associated with a worse prognosis include advanced stage at diagnosis, poor performance status, and lack of response to initial therapy. Early diagnosis and aggressive treatment are critical to improving outcomes for patients with PBL.

Conclusion

Plasmablastic lymphoma is a rare and aggressive lymphoma that poses significant diagnostic and therapeutic challenges. Its association with immunosuppression, particularly HIV infection, highlights the importance of maintaining a high index of suspicion in at-risk populations. Ongoing research into the pathogenesis and treatment of PBL is essential to improve the prognosis for patients with this devastating disease.

‎